GTX-102 Phase 3 Results: What We Know, What We’re Still Learning, and Next Steps
FAST’s CSO, Allyson Berent, addresses the Aspire trial results in a candid letter, exploring what the data mean, what questions remain, and how the community will move forward together.
FAST Leaders to Speak at the CNBC Cures Summit on Patient- and Family-Led Advocacy
FAST joins the inaugural CNBC Cures Summit as the only patient advocacy org on stage, spotlighting how family-led models are accelerating rare disease drug development.
FAST announces establishment of associated drug development accelerator AS²Bio
FAST launches AS²Bio, a drug development accelerator building an integrated ecosystem to advance gene therapy, CRISPR, and stem cell programs for Angelman syndrome and beyond.